Optimizing Asthma Care in Primary Practice: Evidence-Based Strategies for Patient-Centered Management

Create Account

Availability

On-Demand

Access expires on Oct 31, 2026

Cost

$0.00

Credit Offered

1.25 AOA Category 1-A Credits

1.25 AMA PRA Category 1 Credits

OVERVIEW
Asthma remains a major public health issue in the U.S., with many patients still uncontrolled despite available treatments and evidence-based guidelines. This leads to preventable ER visits, hospitalizations, and significant costs—over $80 billion annually. The NCQA has updated HEDIS^® for 2026 to include a new measure, Follow-Up After Acute and Urgent Care Visits for Asthma (AAF-E), which tracks if patients ages 5 to 64 receive an outpatient follow-up within 30 days after an asthma-related urgent or emergency visit. The proposed activity is designed to address education and practice gaps in the care of patients with asthma and increase awareness of the new HEDIS^® measure among managed care professionals and primary care providers.

Speakers: Robert Hostoffer, DO, FACOI; Steven Kheloussi, PharmD, MBA, FAMCP; Massoud Mahmoudi, DO, PhD, FACOI, FAOCAL, FACP, FCCP, FAAAAI (Corresponding Speaker); Karla Stoermer Grossman, MSA, BSN, RN, AE-C

Email the corresponding speaker.

OBJECTIVES

Recognize the goals of asthma care, review barriers to appropriate care, and identify opportunities to implement patient-centered decision making
Identify evidence-based asthma therapies that align with current clinical guidelines
Evaluate how a multidisciplinary team can reduce diagnostic and treatment delays and improve delivery of asthma care
Describe opportunities for primary care to partner with managed care professionals to support coordinated care and ensure patient access to appropriate asthma therapy

Expiration Date: June 30, 2027

This activity is designated for a maximum of 1.25 AOA Category 1-A Credits or 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an independent medical educational grant from AstraZeneca Pharmaceuticals.